Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's SyndromeJennifer L. Crombie, Matthew S. Davids, Lisa Brennan et al.|Blood|2020Cited by 14
Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell LymphomaAustin I. Kim, Mark A. Murakami, Philippe Armand et al.|Blood|2023Cited by 6